Increased VTE Risk with Baricitinib The RA-BRIDGE and RA-BRANCH studies were presented as a late-breaking abstract at EULAR 2026 (LB0009). This was the pooled results from two large FDA post-marketing commitment safety trials — RA-BRIDGE (global) and RA-BRANCH (US-only) — https://t.co/5cQ829x77u

The congress may be over, but the learning continues. RheumNow's EULAR 2026 coverage hub brings together expert reporting, clinical commentary, daily recaps, podcasts, and key takeaways from the meeting's most important presentations. Catch up on: ✔️ Rheumatoid Arthritis ✔️ https://t.co/TU6zIOvIy3

Induction of Cure in Early Arthritis treated early DMARD-naïve Undiff. Arthritis (≥2 joints) w/ NSAIDs (29), MTX 15-25/wk (28), or baricitinib 4 mg/d (28) x 3 mos. Entry DAS ~ 2.4 w/ 2-3 SJC, <17%CCP+. @3 mos Bari > NSAID (DAS−0.52;p=0.01) = MTX (−0.39, p=0.09).@1yr MTX DAS https://t.co/1kKjginhKM

An IL-23i through ~5 years: How did clinical manifestations of PsA and radiographic progression change during long-term treatment? 🔥View the latest long-term data from ACR to find out more. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/JvH74D2ocI https://t.co/4N1kW214Ak

HPV Vaccination in Rheumatic Diseases Dr. Bella Mehta reports on abstract OP0225 presented at the 2026 EULAR Congress meeting in London. https://t.co/PMJ7U9kASW https://t.co/aqoNl3B4Vc

20% sample of elder RA Medicare pts (2009-2022) on TNFi who either stopped or tapered TNFi found 38% sustained de-escalation, while 62% re-escalated within a medianof 164. Re-escalation was more likely in Blacks, Hispanic/other, with a lower comorbidity burden. https://t.co/rEB3VdOii2

Imaging in SpA: are we seeing a clearer picture? The diagnosis of SpA is highly dependent on imaging particularly in a young patient with chronic, inflammatory back pain. It is timely enough since there have been rapid developments in imaging techniques like MRI, Ultrasound and https://t.co/mCPwzGAEVv

US telehealth utilization rose 10.1% in 1st quarter of 2026 (5% to 5.51% medical claims). Most use in mental health conditions (52%) w/ joint/soft tissue dz at 3% overall, higher in west & NE states. 57% for outpt visits, only 7.7% for new visits. 35% for psychotherapy services. https://t.co/L8c7p3iQPL

From BiTE to TriTE: Progress of T-cell Engagers in RMDs At EULAR 2026 in London, T-cell engagers drew attention as a strategy to achieve deep B-cell depletion and drug-free remission in refractory RMDs. BiTEs offer off-the-shelf availability, reversible toxicity from short https://t.co/o8Tn77aYRg

Nature has published that Hyperglycosylation is a metabolic driver of Alzheimer’s Dz (AD) & Glucosamine (GS; taken by ~7% over 70yrs) & GS may increase hyperglycosylation. A retrosp EHR study of AD pts shows glucosamine use assoc w/ accelerated AD progression & worse survival https://t.co/bv6H9h6gAv

Long-term Cancer Risk with Targeted Therapy in SpA Dr. Antoni Chan reports on abstract OP0238 presented at EULAR 2026 in London https://t.co/f67SvKI6Vk https://t.co/fPp2H0aMoK

In the psoriasis-to-PsA transition study at EULAR 2026, which ultrasound finding best distinguished progressing from stable subclinical PsA? Test your knowledge in this week's RheumIQ quiz at https://t.co/Fnzn4UPu0n https://t.co/kV0zA7qyg7